DoW Arthritis Clinical Research Award

<p><strong>Summary: </strong>The fiscal year 2026 (FY26) Arthritis Research Program (ATRP) Clinical Research Award (CRA) supports clinical research that evaluates disease-specific factors and interventions. <em>Research is intended to generate clinically useful evidence with potential to optimize patient outcomes and inform clinical care or policy. Research addressing any and all types of arthritis is encouraged.</em></p><p><br></p><p>Applications must address one of two FY26 ATRP CRA Focus Areas: Prevention and Early Diagnosis, or Treatment and Mitigation of Disease Progression/Burden.</p><p><br></p><p><strong>Distinctive Features:</strong> The FY26 ATRP CRA offers funding for two research levels. It is the responsibility of the applicant to select the level that aligns with the scope of the proposed research.</p><p><br></p><p>• <strong>Research Level 1: </strong>Applications proposing clinical research or early-phase/pilot clinical trials, to include new or emerging research that is not ready for a full-scale randomized controlled clinical trial.</p><p>• <strong>Research Level 2:</strong> Applications proposing a full-scale clinical trial.</p><p><br></p><p>Applications should include a community collaborator (e.g., patient/care partner, community-based organization consultant) who will provide advice and consultation during study design and throughout study planning and implementation. The ATRP encourages a community collaborator for Research Level 1 applications and requires a community collaborator for Research Level 2 applications.</p><p><br></p><p>Preliminary and/or published data are required.</p>